SILAC quantitative proteomics analysis of ivermectin-related proteomic profiling and molecular network alterations in human ovarian cancer cells
- PMID: 33047383
- DOI: 10.1002/jms.4659
SILAC quantitative proteomics analysis of ivermectin-related proteomic profiling and molecular network alterations in human ovarian cancer cells
Abstract
The antiparasitic agent ivermectin offers more promises to treat a diverse range of diseases. However, a comprehensive proteomic analysis of ivermectin-treated ovarian cancer (OC) cells has not been performed. This study sought to identify ivermectin-related proteomic profiling and molecular network alterations in human OC cells. Stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics was used to study the human OC TOV-21G cells. After TOV-21G cells underwent 10 passages in SILAC-labeled growth media, TOV-21G cells were treated with 10 ml of 20 μmol/L ivermectin in cell growing medium for 24 h. The SILAC-labeled proteins were digested with trypsin; tryptic peptides were identified with mass spectrometry (MS). Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was used to mine signaling pathway alterations with ivermectin-related proteins in TOV-21G cells. Gene ontology (GO) analysis was used to explore biological functions of ivermectin-related proteins, including biological processes (BPs), cellular components (CCs), and molecular functions (MFs). The protein-protein interaction network was analyzed with molecular complex detection (MCODE) to identify hub modules. In total, 4,447 proteins were identified in ivermectin-treated TOV-21G cells. KEGG analysis revealed 89 statistically significant signaling pathways. Interestingly, the clustering analysis of these pathways showed that ivermectin was involved in various cancer pathogenesis processes, including modulation of replication, RNA metabolism, and translational machinery. GO analysis revealed 69 statistically significant CCs, 87 MFs, and 62 BPs. Furthermore, MCODE analysis identified five hub modules, including 147 hub molecules. Those hub modules involved ribosomal proteins, RNA-binding proteins, cell-cycle progression-related proteins, proteasome subunits, and minichromosome maintenance proteins. These findings demonstrate that SILAC quantitative proteomics is an effective method to analyze ivermectin-treated cells, provide the first ivermectin-related proteomic profiling and molecular network alterations in human OC cells, and provide deeper insights into molecular mechanisms and functions of ivermectin to inhibit OC cells.
Keywords: biomarker; ivermectin; molecular network; ovarian cancer; quantitative proteomics; stable isotope labeling with amino acids in cell culture.
© 2020 John Wiley & Sons, Ltd.
Similar articles
-
Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment.J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22. J Cell Physiol. 2021. PMID: 32959892 Free PMC article.
-
Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine.EPMA J. 2020 Oct 10;11(4):661-694. doi: 10.1007/s13167-020-00224-z. eCollection 2020 Dec. EPMA J. 2020. PMID: 33240452 Free PMC article.
-
Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes.EPMA J. 2020 May 28;11(2):289-309. doi: 10.1007/s13167-020-00209-y. eCollection 2020 Jun. EPMA J. 2020. PMID: 32549918 Free PMC article.
-
MASS SPECTROMETRY-BASED MITOCHONDRIAL PROTEOMICS IN HUMAN OVARIAN CANCERS.Mass Spectrom Rev. 2020 Sep;39(5-6):471-498. doi: 10.1002/mas.21618. Epub 2020 Feb 4. Mass Spectrom Rev. 2020. PMID: 32020673 Review.
-
Advances in stable isotope labeling: dynamic labeling for spatial and temporal proteomic analysis.Mol Omics. 2022 Aug 15;18(7):579-590. doi: 10.1039/d2mo00077f. Mol Omics. 2022. PMID: 35723214 Free PMC article. Review.
Cited by
-
Quantitative proteomics characterization of cancer biomarkers and treatment.Mol Ther Oncolytics. 2021 Apr 20;21:255-263. doi: 10.1016/j.omto.2021.04.006. eCollection 2021 Jun 25. Mol Ther Oncolytics. 2021. PMID: 34095463 Free PMC article. Review.
-
Quantifiable peptide library bridges the gap for proteomics based biomarker discovery and validation on breast cancer.Sci Rep. 2023 Jun 2;13(1):8991. doi: 10.1038/s41598-023-36159-4. Sci Rep. 2023. PMID: 37268731 Free PMC article.
-
Capturing Biomarkers and Molecular _targets in Cellular Landscapes From Dynamic Reaction Network Models and Machine Learning.Front Oncol. 2022 Jan 21;11:805592. doi: 10.3389/fonc.2021.805592. eCollection 2021. Front Oncol. 2022. PMID: 35127516 Free PMC article. Review.
-
Linkage and association analyses reveal that hub genes in energy-flow and lipid biosynthesis pathways form a cluster in upland cotton.Comput Struct Biotechnol J. 2022 Apr 15;20:1841-1859. doi: 10.1016/j.csbj.2022.04.012. eCollection 2022. Comput Struct Biotechnol J. 2022. PMID: 35521543 Free PMC article.
References
REFERENCES
-
- Burg RW, Miller BM, Baker EE, et al. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother. 1979;15(3):361-367.
-
- Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. J Antibiot (Tokyo). 2017;70(5):495-505.
-
- Laing R, Gillan V, Devaney E. Ivermectin-old drug, new tricks? Trends Parasitol. 2017;33(6):463-472.
-
- Li N, Zhan X. Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes. EPMA J. 2020;11(2):289-309.
-
- Liu J, Zhang K, Cheng L, Zhu H, Xu T. Progress in understanding the molecular mechanisms underlying the antitumour effects of ivermectin. Drug Des Devel Ther. 2020;14:285-296.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical